Open AccessReceptor Tyrosine Kinases and Inhibitors in Lung Cancer
Author(s) -
Evan Pisick,
Simha Jagadeesh,
Ravi Salgia
Publication year - 2004
Publication title -
the scientific world journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.453
H-Index - 93
eISSN - 2356-6140
pISSN - 1537-744X
DOI - 10.1100/tsw.2004.117
Subject(s) - receptor tyrosine kinase , epidermal growth factor receptor , cancer research , tyrosine kinase , lung cancer , receptor protein tyrosine kinases , receptor , growth factor receptor , erythropoietin producing hepatocellular (eph) receptor , insulin like growth factor 1 receptor , medicine , small cell lung carcinoma , biology , ror1 , growth factor , platelet derived growth factor receptor , small cell carcinoma
Lung cancer is a deadly disease with high mortality and morbidity. Most cases of lung cancer are due to non-small cell carcinoma, with 16% of cases being small cell carcinoma. The biology at a cellular level is of interest at many levels. Knowing cellular pathways helps to further enhance our knowledge of how lung cancer cells survive, proliferate, and metastasize. The receptor tyrosine kinases (RTKs) located at the cellular membrane are becoming of great interest as sites for targeted therapies for lung cancers. This review will discuss the RTKs that are involved in lung cancers and the newer therapies that are being tested. We will specifically discuss receptors such as epidermal growth factor receptor, c-Kit receptor, VEGF receptor, c-Met receptor, insulin growth factor receptor, and Eph receptor. The inhibitors against the specific RTKs are in various preclinical and clinical trials, and this will be detailed.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom